GlassScriptPhysician profile
Patrick Gorman Shepherd
NPI 1629561493
$824.17
in general payments reported to CMS, 2019-2025
14 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.24 · 2022: $195 · 2023: $196 · 2024: $160 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $348.32 | 2022-2025 | |
| Glaxosmithkline, LLC. | $112.43 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $52.77 | 2022-2024 | |
| Lilly USA, LLC | $52.72 | 2022-2024 | Mounjaro, Zepbound |
| Genentech USA, INC. | $48.24 | 2021 | |
| Axsome Therapeutics, INC. | $43.41 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $39.27 | 2022-2025 | Airsupra |
| Novo Nordisk INC | $28.68 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $25.96 | 2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $17.21 | 2022 | |
| Exact Sciences Corporation | $14.26 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $13.69 | 2024 | Xarelto |
| Boston Scientific Corporation | $13.14 | 2024 | Varithena Administration Pack |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.